Floatz logo

Cetuximab

Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity

Fox Chase Cancer Centermonoclonal_antibodyPhase 1/2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity cohort.

Asset / SponsorPhaseRating
Irinotecan
AIDS Malignancy Consortium
Phase 1/2B
Everolimus
Fox Chase Cancer Center
Phase 1CC
Alvespimycin
National Cancer Institute (NCI)
Phase 1CC
7-hydroxystaurosporine
National Cancer Institute (NCI)
Phase 1CC
Carboplatin
AIDS Malignancy Consortium
Phase 1CC
Vorinostat
AIDS Malignancy Consortium
Phase 1CC
(11-L-THREONINE, 29-L-ARGININE)LACTOFERRIN(HUMAN) PRODUCED BY ASPERGILLUS NIGER VAR. AWAMORI
Stanford University
Phase 1CC
Gefetinib
National Cancer Institute (NCI)
N/AD

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →